As in­vestors fret about Xyrem dura­bil­i­ty, Jazz spends $52M+ up­front to swal­low neu­ro-fo­cused biotech

With in­vestors get­ting jit­tery about the dura­bil­i­ty of Jazz Phar­ma’s cash-cow Xyrem, the spe­cial­ty bio­phar­ma­ceu­ti­cal drug­mak­er is ex­pand­ing its port­fo­lio with the pur­chase of Cavion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER